THU181 Evaluation Of Bone Mineral Density In A Cohort Of Children With ACH Participating In The PROPEL 2 Study Of Infigratinib

Disclosure: R. Savarirayan: Advisory Board Member; Self; Ascendis Pharma, BioMarin, QED Therapeutics, Sanofi, Sanofi. Consulting Fee; Self; BioMarin. Grant Recipient; Self; Ascendis Pharma, BioMarin, QED Therapeutics, Therachon. Research Investigator; Self; Ascendis Pharma, BioMarin, QED Therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Savarirayan, Ravi, De Bergua, Josep Maria, Arundel, Paul, Salles, Jean Pierre, Leiva-Gea, Antonio, Irving, Melita, Saraff, Vrinda, McDevitt, Helen, Salcedo, Maria, Nicolino, Marc P, Cormier-Daire, Valerie, Kannu, Peter, Skae, Mars, Bober, Michael B, Phillips III, John, Candler, Toby, Harmatz, Paul, Saal, Howard, Hoover-Fong, Julie, Muslimova, Elena, Cho, Terry, Weng, Richard, Rogoff, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Pediatric Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553972/
http://dx.doi.org/10.1210/jendso/bvad114.1432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553972/
http://dx.doi.org/10.1210/jendso/bvad114.1432

Ejemplares similares